Across TCGA pan-cancer cohorts, TRBV21OR9-2 RNA is linked to patient survival in 12 of 34 cancer types, making it the most broadly survival-associated TRBV21OR9-2 data layer compared with 6 for mutation status.
The strongest signal is observed in uterine carcinosarcoma (UCS), where higher TRBV21OR9-2 RNA is associated with better disease-free survival. In most high-consensus cancer types, elevated TRBV21OR9-2 expression acts as an unfavorable survival marker, although some lineages such as UCS and STAD show a favorable association.
UCS, BLCA, and UCEC are the cancer types where TRBV21OR9-2 RNA most reproducibly stratifies survival.
RNA survival associations by lineage
Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.